You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Incidence of Peptic Ulcer Bleeding in the US Pediatric Population

Brown, Kurt*; Lundborg, Per; Levinson, Jeremy*; Yang, Huiying*

Journal of Pediatric Gastroenterology & Nutrition:
doi: 10.1097/MPG.0b013e31824fb7f9
Original Articles: Gastroenterology

Objectives: The aim of the present study was to determine the incidence of peptic ulcer bleeding (PUB) in pediatric patients.

Methods: A hospital inpatient database, Premier Perspective, and an insurance claims database, MarketScan, were analyzed to estimate upper and lower limits for the annual incidence of PUB in the US pediatric population.

Results: Using data from the Premier Perspective database and database-specific projection methodology, the total number of cases of hospitalization of pediatric patients for PUB in the United States in 2008 was estimated to be between 378 and 652. This translated to an incidence of 0.5 to 0.9/100,000 individuals in the pediatric population. Using data from the MarketScan database, the incidence of PUB in the insured pediatric population was estimated to be 4.4/100,000 individuals. Overall, 17.4% of insured pediatric patients diagnosed as having any upper gastrointestinal ulcer in 2008 were reported to have developed PUB.

Conclusions: The estimated incidence of PUB in the US pediatric population in 2008 ranged from 0.5 to 4.4/100,000 individuals. The total number of cases of PUB in pediatric patients in the United States each year was thus estimated to be between 378 and 3250. Such estimates provide a likely lower and upper limit for the total number of cases of the condition annually.

Author Information

*AstraZeneca R&D, Wilmington, DE

AstraZeneca R&D, Mölndal, Sweden.

Address correspondence and reprint requests to Kurt Brown, MD, AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19850 (e-mail:

Received 11 November, 2011

Accepted 10 February, 2012

The present study was supported by AstraZeneca R&D. All of the authors are employees of AstraZeneca.

Copyright 2012 by ESPGHAN and NASPGHAN